Genentech, Inc.

Dade Behring Marburg Gmbh

Genetech, Inc.

Maureen H Beresini

Austin L Gurney

William I Wood

Audrey Goddard

Paul J Godowski

Victoria Smith

Colin K Watanabe

Luc Roland Desnoyers

Kevin P Baker

Ellen Filvaroff

Daniel Tumas

Timothy Andrew Stewart

Zemin Zhang

Mary E Gerritsen

Wei-Qiang Gao

Steven W Sherwood

Laura Deforge

Edwin F Ullman

Dariush Davalian

Svetlana Alexander

Wei Ey Li

Robert A Lazarus

Daniel Kirchhofer

Yingnan Zhang

Daniel J Burdick

Nicholas Skelton

Mark Ultsch

Charles Eigenbrot, Jr

John Quinn

Mae Wan-Leng Hu

Mae W Hu

The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.

Compositions and methods for treating cardiovascular disease

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

PRO350 antibodies

The present invention is directed to novel PRO1475 polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the PRO1475 polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the PRO1475 polypeptides of the present invention and to methods for producing the PRO1475 polypeptides of the present invention.

PRO1475 polypeptide

Anti-PRO6181 antibodies

PRO6097 polypeptides

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Pro4428 Polypeptides

Pro1782 polypeptides

PRO1338 polypeptides

Nucleic acids encoding PRO4400 polypeptides

A method of measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is disclosed. A method of inactivating interfering cross-reactive material in an assay for measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is also disclosed. Compositions wherein cyclosporin is conjugated to an immunogenic carrier or a label, optionally through a linking group, at an alanine nitrogen atom of the cyclic backbone of cyclosporin are also disclosed. Compositions wherein atiocyclosporin is conjugated, optionally through a linking group, to an immunogenic carrier or a label are also disclosed. Where cyclosporin is conjugated to an immunogenic carrier, the conjugates may be used as immunogens for the preparation of antibodies which are capable of recognizing cyclosporin. Where atiocyclosporin is conjugated to an immunogenic carrier, the conjugates may be used as immunogens for the preparation of antibodies which are capable of recognizing interfering cross-reactive material but substantially incapable of recognizing cyclosporin or cyclosporin-label conjugates. Where cyclosporin is conjugated to a label, the conjugates may be used as part of a signal producing system in cyclosporin assays. Both the antibodies and label conjugates are useful in the disclosed assay methods.

Cyclosporin immunoassay

Cyclosporin assay and kit

Growing community of inventors

Moss Beach, CA, United States of America

Maureen H Beresini